Andrew Tutt
Impact in
- Oncology top 0.02%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Papers in
- Oncology 98
- PARP inhibition in cancer therapy 48
- HER2/EGFR in Cancer Research 13
-
- DNA Repair Mechanisms 40
- CRISPR and Genetic Engineering 13
- Co-authors
- Alan Ashworth (18 shared papers)Christopher J. Lord (23 shared papers)Nicholas C. Turner (14 shared papers)Alan Ashworth (6 shared papers)Nuala McCabe (4 shared papers)Graeme C.M. Smith (4 shared papers)James Carmichael (4 shared papers)J. S. Reis-Filho (2 shared papers)
- Journals
- Journal of Clinical Oncology (25 papers)Cancer Research (12 papers)Annals of Oncology (9 papers)Breast Cancer Research (5 papers)Oncogene (5 papers)
- Partner nations
- United KingdomUnited StatesBelgium
In The Last Decade
Andrew Tutt
151 papers receiving 23.9k citations
Andrew Tutt's Hit Papers
Peers
Comparison fields: 5 of 137
- Oncology 14.3k
- Cancer Research 5.0k
- Reproductive Medicine 1.6k
- Molecular Biology 12.7k
- Genetics 4.3k
Countries citing papers authored by Andrew Tutt
This map shows the geographic impact of Andrew Tutt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Tutt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Tutt more than expected).
Fields of papers citing papers by Andrew Tutt
This network shows the impact of papers produced by Andrew Tutt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Tutt. The network helps show where Andrew Tutt may publish in the future.
Co-authors
The 25 scholars most cited alongside Andrew Tutt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 156 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Hit paper breakdown → | 2005 | 4810 |
| 2 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 2716 |
| 3 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1748 |
| 4 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1296 |
| 5 | Hallmarks of 'BRCAness' in sporadic cancers Hit paper breakdown → | 2004 | 1250 |
| 6 | Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition Hit paper breakdown → | 2006 | 989 |
| 7 | Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Hit paper breakdown → | 2010 | 753 |
| 8 | Triple negative tumours: a critical review Hit paper breakdown → | 2007 | 707 |
| 9 | Molecular alterations in triple-negative breast cancer—the road to new treatment strategies Hit paper breakdown → | 2016 | 670 |
| 10 | BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells Hit paper breakdown → | 2010 | 561 |
| 11 | FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer Hit paper breakdown → | 2010 | 551 |
| 12 | A decade of clinical development of PARP inhibitors in perspective Hit paper breakdown → | 2019 | 512 |
| 13 | 2006 | 439 | |
| 14 | 2012 | 360 | |
| 15 | 2011 | 358 | |
| 16 | Targeting folate receptor alpha for cancer treatment Hit paper breakdown → | 2016 | 355 |
| 17 | 2014 | 346 | |
| 18 | 2001 | 344 | |
| 19 | 2010 | 288 | |
| 20 | 1999 | 264 |
About Andrew Tutt
Andrew Tutt is a scholar working on Oncology, Molecular Biology, Cancer Research, Genetics and Pulmonary and Respiratory Medicine, having authored 156 papers that have together received 24.3k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (48 papers), DNA Repair Mechanisms (40 papers), BRCA gene mutations in cancer (37 papers), Breast Cancer Treatment Studies (25 papers), Cancer Genomics and Diagnostics (20 papers), Advanced Breast Cancer Therapies (19 papers), HER2/EGFR in Cancer Research (13 papers) and CRISPR and Genetic Engineering (13 papers). The work is most often cited by research in Oncology (14.3k citations), Cancer Research (5.0k citations), Reproductive Medicine (1.6k citations), Molecular Biology (12.7k citations) and Genetics (4.3k citations). Andrew Tutt has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include Alan Ashworth, Christopher J. Lord, Nicholas C. Turner, Alan Ashworth, Nuala McCabe, Graeme C.M. Smith, James Carmichael, J. S. Reis-Filho, Niall M.B. Martin and Stephen P. Jackson. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.